ACTG 5332 (REPRIEVE): In this study, people between the ages of 40 and 75 with HIV will be randomized (like flipping a coin) to take the pill pitavastatin OR a placebo (non-active pill) to see if pitavastatin can help prevent heart disease and death in people who are taking HIV medication.

ACTG 5360: This Minimal Monitoring study investigated the efficacy of Hepatitis C treatment that requires fewer in-person visits and less laboratory monitoring to overcome access and health equity issues in Hep C treatment. Research found that self-reported 100 percent adherence in the first four weeks of hepatitis C treatment with sofosbuvir/velpatasvir was associated with sustained virologic response.